Below are Gilead’s Research Scholar Program Hematologic Malignancies Awardees and their research titles. As the program values diverse voices and innovative research topics to address areas of unmet medical need, you do not need to duplicate previous research topics in order to be successful for an Award.
Any clinical or basic research proposal that addresses an area of unmet medical need in Hematologic Malignancies is welcome.
For other examples of exceptional applications, please visit the NIH’s RO1 sample applications through this helpful resource: https://www.niaid.nih.gov/grants-contracts/sample-applications
2022 Award Recipients
Theodore P. Braun, MD, PhD
Oregon Health & Science University
Therapeutic Targeting of YBX1 in Myeloid Malignancies
Sizun Jiang, PhD
Beth Israel Deaconess Medical Center
Spatial-temporal dynamics of CAR and non-CAR T cell orchestrated immune responses in the intact DLBCL tumor microenvironment
Paolo Strati, MD
UT MD Anderson Cancer Center
Targeting Macrophages for the Treatment of B-cell Lymphoma
2020 Award Recipients
Christopher Ott, PhD
Massachusetts General Hospital
Investigation of a novel bromodomain addiction in multiple myeloma
Maria Guillamot Runao, PhD, PharmD
NYU Langone
Epigenetic mechanisms of clonal evolution triggered by infections
Alan Shih, MD, PhD
Icahn School of Medicine at Mount Sinai
TET2 and Inflammation in Myeloid Disease
Anastasia Tikhonova, PhD
Princess Margaret Cancer Center
Dissecting Immune Microenvironment of adult T-cell acute lymphoblastic leukemia
2019 Award Recipients
Julia Maxson, PhD
Oregon Health & Science University
“Mechanisms of SETBP1-driven Oncogenesis in Myeloid Leukemia”
Marco Ruella, MD, MS
University of Pennsylvania
“Genetic Inactivation of CD5 in Normal T Cells to Enable Safe and Effective CAR T Cell Immunotherapy for T cell Lymphomas”
Peter van Galen, PhD
Harvard Medical School
“Targeting Survival Mechanisms of Persistent Acute Myeloid Leukemia Cells”
2018 Award Recipients
Saad S. Kenderian, MD
Mayo Clinic
"Depletion of GM-CSF and Myeloid Cells as a Strategy to Enhance The Therapeutic Index After Chimeric Antigen Receptor T (CART) Cell Therapy"
Robert Kridel, MD, MPH, PhD
Princess Margaret Cancer Centre
"Rational Prioritization of Drug Combinations to Overcome Resistance to Tazemetostat in Germinal Centre B-cell Lymphoma"
Xiaolei Su, PhD
Yale School of Medicine
"Molecular Mechanism of CAR Activation in Targeting B Cell Leukemia and Lymphoma"
2017 Award Recipients
Sergei Doulatov, PhD
University of Washington
“Patient-Derived MDS Stem Cells from Pluripotent Stem Cells”
Alex F. Herrera, MD
Beckman Research Institute of City of Hope
“Immunogenic Chemotherapy and Checkpoint Inhibition for Transformed Diffuse Large B-Cell Lymphoma”
Panagiotis Ntziachristos, PhD
Northwestern University
“Targeting Aberrant Levels of the Splicing Factor SF3B1 as a Therapeutic Strategy in High-Risk T-Cell Leukemia"
2016 Award Recipients
Emily Curran, MD
University of Chicago
“Immunologic Role of DDX41 in Development of Hereditary Hematologic Malignancies”
Gang Greg Wang, PhD
University of North Carolina, Chapel Hill
“Decipher and Target Epigenetic Dependency in Acute Myeloid Leukemia with DNMT3A Mutation”
Britta Will, PhD
Albert Einstein College of Medicine
“Targeting Chaperone-Mediated Autophagy for the Eradication of Acute Myeloid Leukemia”
2015 Award Recipients
Steven Chan, MD, PhD
Princess Margaret Cancer Center University of Toronto
“Determination of the Clonal Architecture and Functional Impact of Mitochondrial DNA Mutations in Acute Myeloid Leukemia”
Shangqin Guo, PhD
Yale University Stem Cell Center
“Molecular Definition of Leukemia Cell-of-Origin”
Raajit Rampal, MD, PhD
Memorial Sloan Kettering Cancer Center
“Identification of Novel Therapeutic Strategies for Acute Myeloid Leukemia Arising from a Myeloproliferative Neoplasm”
2014 Award Recipients
Luca Busino, PhD
University of Pennsylvania
“Relevance of KLHL6-mediated Protein Degradation in the Pathogenesis of B-cell Lymphoma”
Phuong Doan, MD
Duke University
“Epidermal Growth Factor Regulates MDS Stem Cell Fate”
- GILEAD and the GILEAD logo are registered
- trademarks of Gilead Sciences, Inc., or one of its related companies. Kite
- and the Kite Logo are registered trademarks of Kite, a Gilead company.
- © 2022 Gilead Sciences, Inc. All rights reserved.